[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.129.96. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 1983

Commentary: Use of Topical Fluorouracil

Author Affiliations

From the Department of Dermatology, University of Arkansas for Medical Sciences, Little Rock.

Arch Dermatol. 1983;119(9):784-785. doi:10.1001/archderm.1983.01650330076016
Abstract

I deeply appreciate the opportunity to reflect on our early experiences with topical fluorouracil at the University of Arkansas, Little Rock. It is difficult for me to realize that 20 years have passed, and I was filled with sadness when I reread the article, knowing that the bright young minds of Calvin Dillaha, MD, and W. Mage Honeycutt, MD, are no longer here to share in this review.1 Their early deaths were a deep personal loss.

Early in 1962, Fred J. Ansfield, MD, was a guest speaker of our local medical society and brought to Little Rock an update of the use of intravenous (IV) fluorouracil in the treatment of metastatic disease. During his speech he mentioned the alterations in the skin that occurred, especially across the face and other sun-exposed sites. We were aware of the observations of Falkson and Schulz2 on the photodermatitis-like changes following the

First Page Preview View Large
First page PDF preview
First page PDF preview
×